IL17RE

Summary

IL17RE (interleukin 17 receptor E, HGNC:18439) is a protein-coding gene on chromosome 3p25.3, encoding Interleukin-17 receptor E (Q8NFR9). Specific functional receptor for IL17C.

This gene encodes a transmembrane protein that functions as the receptor for interleukin-17C. The encoded protein signals to downstream components of the mitogen activated protein kinase (MAPK) pathway. Activity of this protein is important in the immune response to bacterial pathogens. Alternatively spliced transcript variants have been described for this gene.

Source: NCBI Gene 132014 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 133 total
• Druggable target: yes
• MANE Select transcript: NM_153480

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:18439
Approved symbol	IL17RE
Name	interleukin 17 receptor E
Location	3p25.3
Locus type	gene with protein product
Status	Approved
Aliases	FLJ23658
Ensembl gene	ENSG00000163701
Ensembl biotype	protein_coding
OMIM	614995
Entrez	132014

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 5 protein_coding, 4 retained_intron, 3 nonsense_mediated_decay

ENST00000383814, ENST00000383815, ENST00000421412, ENST00000434065, ENST00000444427, ENST00000454190, ENST00000454992, ENST00000461534, ENST00000480244, ENST00000483258, ENST00000489181, ENST00000865435

RefSeq mRNA: 4 — MANE Select: NM_153480 NM_001193380, NM_153480, NM_153481, NM_153483

CCDS: CCDS2589, CCDS54552

Canonical transcript exons

ENST00000383814 — 16 exons

Exon	Start	End
ENSE00001673130	9902848	9903064
ENSE00003463832	9911255	9911300
ENSE00003468219	9906961	9907100
ENSE00003477714	9911443	9911597
ENSE00003498024	9914679	9914777
ENSE00003525226	9909217	9909283
ENSE00003536940	9914548	9914599
ENSE00003547703	9904032	9904151
ENSE00003551903	9906364	9906461
ENSE00003571202	9908239	9908307
ENSE00003574507	9910865	9911040
ENSE00003579256	9913956	9914024
ENSE00003584249	9906706	9906865
ENSE00003618944	9903397	9903412
ENSE00003661473	9911127	9911174
ENSE00003674172	9915251	9916397

Expression profiles

Bgee: expression breadth ubiquitous, 156 present calls, max score 94.30.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 5.5066 / max 167.4590, expressed in 969 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
35251	5.0515	929
35250	0.4551	217

Top tissues by expression

245 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
skin of leg	UBERON:0001511	94.30	gold quality
skin of abdomen	UBERON:0001416	93.75	gold quality
mucosa of transverse colon	UBERON:0004991	93.65	gold quality
rectum	UBERON:0001052	92.51	gold quality
zone of skin	UBERON:0000014	89.78	gold quality
transverse colon	UBERON:0001157	88.97	gold quality
right coronary artery	UBERON:0001625	88.49	gold quality
small intestine Peyer’s patch	UBERON:0003454	87.42	gold quality
body of stomach	UBERON:0001161	87.30	gold quality
cerebellar hemisphere	UBERON:0002245	87.30	gold quality
lower esophagus mucosa	UBERON:0035834	87.24	gold quality
cerebellar cortex	UBERON:0002129	87.11	gold quality
right hemisphere of cerebellum	UBERON:0014890	86.88	gold quality
popliteal artery	UBERON:0002250	85.65	gold quality
tibial artery	UBERON:0007610	85.62	gold quality
body of pancreas	UBERON:0001150	85.27	gold quality
esophagus mucosa	UBERON:0002469	85.23	gold quality
left coronary artery	UBERON:0001626	85.20	gold quality
minor salivary gland	UBERON:0001830	85.12	gold quality
small intestine	UBERON:0002108	85.00	gold quality
cerebellum	UBERON:0002037	84.39	gold quality
stomach	UBERON:0000945	84.37	gold quality
gall bladder	UBERON:0002110	84.18	gold quality
aorta	UBERON:0000947	83.25	gold quality
coronary artery	UBERON:0001621	83.05	gold quality
descending thoracic aorta	UBERON:0002345	82.14	gold quality
right lung	UBERON:0002167	81.59	gold quality
upper lobe of left lung	UBERON:0008952	80.90	gold quality
saliva-secreting gland	UBERON:0001044	80.65	gold quality
pancreas	UBERON:0001264	80.61	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.09
E-GEOD-100618	no	10.29

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

20 targeting IL17RE, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-4745-5P	99.98	65.95	1028
HSA-MIR-589-3P	99.91	69.62	2088
HSA-MIR-6739-5P	99.80	67.87	2806
HSA-MIR-1299	99.77	71.24	2389
HSA-MIR-6733-5P	99.74	67.94	2759
HSA-MIR-6512-3P	99.65	66.07	1468
HSA-MIR-6720-5P	99.65	66.22	1459
HSA-MIR-516B-5P	99.56	66.33	1495
HSA-MIR-3153	99.55	67.59	2337
HSA-MIR-12123	99.52	71.79	2990
HSA-MIR-4316	99.37	65.75	1360
HSA-MIR-4667-3P	99.26	65.45	1608
HSA-MIR-4784	99.15	67.41	1733
HSA-MIR-6814-5P	99.03	66.68	1273
HSA-MIR-511-5P	98.97	70.94	2268
HSA-MIR-4782-5P	98.35	69.33	1474
HSA-MIR-5706	98.35	69.33	1463
HSA-MIR-505-5P	97.01	65.54	778
HSA-MIR-4264	96.35	64.76	1480

Literature-anchored findings (GeneRIF, showing 6)

• IL-17RE as a receptor of IL-17C that regulates early innate immunity to intestinal pathogens. (PMID:21993849)
• Our findings suggest that the IL-25/IL-25R axis may play an important role in promoting the recruitment and proinflammatory function of eosinophils in allergic asthma. (PMID:27685606)
• Evaluation of Interleukin 25 and Interleukin 25 Receptor Expression in Peripheral Blood Mononuclear Cells of Breast Cancer Patients and Normal Subjects. (PMID:31905037)
• IL-17C/IL-17RE: Emergence of a Unique Axis in TH17 Biology. (PMID:32174926)
• Interleukin 17 receptor E identifies heterogeneous T helper 17 cells in peritoneal fluid of moderate and severe endometriosis patients. (PMID:35553626)
• Clinical significance of Interleukin 17 receptor E in diabetic nephropathy. (PMID:37235960)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Il17re	ENSMUSG00000043088
rattus_norvegicus	Il17re	ENSRNOG00000009204

Paralogs (4): IL17RB (ENSG00000056736), IL17RD (ENSG00000144730), IL17RC (ENSG00000163702), IL17RA (ENSG00000177663)

Protein

Protein identifiers

Interleukin-17 receptor E — Q8NFR9 (reviewed: Q8NFR9)

All UniProt accessions (6): A6NL85, C9J1R2, Q8NFR9, F8WB54, F8WCU7, J3KQN7

UniProt curated annotations — full annotation on UniProt →

Function. Specific functional receptor for IL17C. May be signaling through the NF-kappa-B and MAPK pathways. May require TRAF3IP2 /ACT1 for signaling. May be a crucial regulator in innate immunity to bacterial pathogens. Isoform 2 and isoform 4 may be either cytoplasmic inactive or dominant active forms. Isoform 3 and isoform 5 may act as soluble decoy receptors.

Subunit / interactions. Forms heterodimers with IL17RA; the heterodimer binds IL17C.

Subcellular location. Cell membrane Cytoplasm Secreted Cytoplasm Secreted.

Tissue specificity. Predominantly expressed in mucosal tissues with high levels in keratinocytes and colon epithelial cells. Very low expression in dermal fibroblasts. Expressed in various tumor cell lines.

Isoforms (5)

UniProt ID	Names	Canonical?
Q8NFR9-1	1	yes
Q8NFR9-2	2
Q8NFR9-3	3
Q8NFR9-4	4
Q8NFR9-5	5

RefSeq proteins (4): NP_001180309, NP_705613, NP_705614, NP_705616 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR013568	SEFIR_dom	Domain
IPR027841	IL-17_rcpt_C/E_N	Domain
IPR039465	IL-17_rcpt-like	Family

Pfam: PF08357, PF15037

UniProt features (22 total): splice variant 7, sequence variant 3, glycosylation site 3, topological domain 2, sequence conflict 2, signal peptide 1, chain 1, transmembrane region 1, domain 1, region of interest 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8NFR9-F1	68.77	0.27

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (3): 318, 347, 364

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-448424	Interleukin-17 signaling

MSigDB gene sets: 99 (showing top): REACTOME_CYTOKINE_SIGNALING_IN_IMMUNE_SYSTEM, GOBP_INFLAMMATORY_RESPONSE, TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, GOBP_RESPONSE_TO_PEPTIDE, RORA1_01, RACCACAR_AML_Q6, AML_Q6, GATA1_01, GOBP_ADAPTIVE_IMMUNE_RESPONSE, GOBP_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, GOBP_PROTEIN_POLYUBIQUITINATION, RYTTCCTG_ETS2_B, GOBP_PROTEIN_K63_LINKED_UBIQUITINATION, RGAGGAARY_PU1_Q6, GOBP_ADAPTIVE_IMMUNE_RESPONSE_BASED_ON_SOMATIC_RECOMBINATION_OF_IMMUNE_RECEPTORS_BUILT_FROM_IMMUNOGLOBULIN_SUPERFAMILY_DOMAINS

GO Biological Process (2): inflammatory response (GO:0006954), cytokine-mediated signaling pathway (GO:0019221)

GO Molecular Function (2): interleukin-17 receptor activity (GO:0030368), protein binding (GO:0005515)

GO Cellular Component (4): extracellular region (GO:0005576), cytoplasm (GO:0005737), plasma membrane (GO:0005886), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Signaling by Interleukins	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
defense response	1
cell surface receptor signaling pathway	1
cellular response to cytokine stimulus	1
cytokine receptor activity	1
interleukin-17 binding	1
binding	1
intracellular anatomical structure	1
membrane	1
cell periphery	1

Protein interactions and networks

STRING

546 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
IL17RE	IL17C	Q9P0M4	996
IL17RE	IL17RA	Q96F46	996
IL17RE	IL17RB	Q9NRM6	986
IL17RE	IL17F	Q96PD4	966
IL17RE	IL17RD	Q8NFM7	959
IL17RE	IL17RC	Q8NAC3	951
IL17RE	IL17B	Q9UHF5	933
IL17RE	IL25	Q9H293	862
IL17RE	IL17D	Q8TAD2	817
IL17RE	IL17A	Q16552	771
IL17RE	IL12RB1	P42701	643
IL17RE	IL1B	P01584	597
IL17RE	CCRL2	O00421	582
IL17RE	CCR6	P51684	572
IL17RE	IL18R1	Q13478	552

IntAct

3 interactions, top by confidence:

A	B	Type	Score
IL17RE	IL17RA	psi-mi:“MI:0915”(physical association)	0.400
IL17RA	IL17RE	psi-mi:“MI:0915”(physical association)	0.400

BioGRID (10): GORAB (Affinity Capture-MS), PPFIA1 (Affinity Capture-MS), HMMR (Affinity Capture-MS), FAM192A (Affinity Capture-MS), ACTA2 (Affinity Capture-MS), PSMG4 (Affinity Capture-MS), PSMG3 (Affinity Capture-MS), ACTBL2 (Affinity Capture-MS), FAT3 (Affinity Capture-MS), IL17RE (Affinity Capture-RNA)

ESM2 similar proteins: A2A9Q0, A5PKD8, A9JSM3, D4A2Q0, E7ERA6, F1SAM7, F2Z333, P0CG25, Q07303, Q0IIA6, Q1RMK9, Q24JP5, Q2MJR0, Q2WF71, Q3MIP1, Q3UV16, Q3ZCQ3, Q504Y2, Q5EBM0, Q5GH56, Q5GH64, Q5GH72, Q5RJI4, Q5SZI1, Q641Q3, Q6IEE6, Q6IQX7, Q6P6N5, Q6UKI2, Q6ZMC9, Q6ZVW7, Q86UD0, Q8IUW3, Q8IZ52, Q8K064, Q8N4K4, Q8NAC3, Q8NBR0, Q8NCL9, Q8NFR9

Diamond homologs: Q6AZ51, Q6ZVW7, Q8BH06, Q8NFR9

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

133 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	95
Likely benign	13
Benign	4

Top pathogenic / likely-pathogenic (0)

SpliceAI

2014 predictions. Top by Δscore:

Variant	Effect	Δscore
3:9903378:ACT:A	acceptor_gain	1.0000
3:9903378:ACTG:A	acceptor_gain	1.0000
3:9903380:T:A	acceptor_gain	1.0000
3:9906704:A:AG	acceptor_gain	1.0000
3:9906705:G:GG	acceptor_gain	1.0000
3:9906705:GA:G	acceptor_gain	1.0000
3:9906830:A:T	donor_gain	1.0000
3:9909280:GCCT:G	donor_gain	1.0000
3:9909284:G:GG	donor_gain	1.0000
3:9911122:CACA:C	acceptor_loss	1.0000
3:9911123:ACAGT:A	acceptor_gain	1.0000
3:9911125:A:AG	acceptor_gain	1.0000
3:9911125:AGT:A	acceptor_gain	1.0000
3:9911125:AGTG:A	acceptor_gain	1.0000
3:9911126:G:GA	acceptor_gain	1.0000
3:9911126:GT:G	acceptor_gain	1.0000
3:9911126:GTG:G	acceptor_gain	1.0000
3:9911126:GTGG:G	acceptor_gain	1.0000
3:9911126:GTGGT:G	acceptor_gain	1.0000
3:9911253:A:AG	acceptor_gain	1.0000
3:9911254:G:GG	acceptor_gain	1.0000
3:9914776:AGGTA:A	donor_loss	1.0000
3:9914777:GGT:G	donor_loss	1.0000
3:9914779:T:G	donor_loss	1.0000
3:9903064:GG:G	donor_loss	0.9900
3:9903065:GTAAG:G	donor_loss	0.9900
3:9903066:T:A	donor_loss	0.9900
3:9903378:A:AG	acceptor_gain	0.9900
3:9903378:ACTGG:A	acceptor_gain	0.9900
3:9903381:G:A	acceptor_gain	0.9900

AlphaMissense

4249 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:9911459:G:C	W363C	0.993
3:9911459:G:T	W363C	0.993
3:9911457:T:A	W363R	0.989
3:9911457:T:C	W363R	0.989
3:9914553:G:C	W434C	0.989
3:9914553:G:T	W434C	0.989
3:9911256:T:C	F343S	0.988
3:9911526:T:C	F386L	0.988
3:9911527:T:C	F386S	0.988
3:9911528:C:A	F386L	0.988
3:9911528:C:G	F386L	0.988
3:9910881:G:C	W273C	0.987
3:9910881:G:T	W273C	0.987
3:9910945:T:C	C295R	0.987
3:9911527:T:G	F386C	0.987
3:9907047:T:A	C205S	0.986
3:9907048:G:C	C205S	0.986
3:9910972:T:C	C304R	0.986
3:9908299:T:C	C243R	0.985
3:9910972:T:A	C304S	0.985
3:9910973:G:C	C304S	0.985
3:9911166:T:C	C340R	0.985
3:9911533:C:A	A388D	0.985
3:9907068:T:A	C212S	0.984
3:9907069:G:C	C212S	0.984
3:9908293:T:C	C241R	0.984
3:9908301:C:G	C243W	0.984
3:9909256:T:A	C259S	0.984
3:9909257:G:C	C259S	0.984
3:9907068:T:C	C212R	0.983

dbSNP variants (sampled 300 via entrez): RS1000257917 (3:9904506 C>G), RS1000337096 (3:9904865 G>A), RS1000408075 (3:9910656 G>T), RS1000501438 (3:9900836 G>A,C), RS1000730993 (3:9902658 C>T), RS1000797285 (3:9904231 A>C), RS1000956351 (3:9900554 T>C), RS1001316357 (3:9905579 G>T), RS1001486518 (3:9911172 A>G), RS1002012242 (3:9901025 T>C), RS1002893870 (3:9906074 A>AC), RS1003085401 (3:9912542 C>T), RS1003158752 (3:9912311 G>A), RS1003335064 (3:9907999 G>A), RS1003461313 (3:9912011 ACTGT>A)

Disease associations

OMIM: gene MIM:614995 | disease phenotypes: MIM:616022, MIM:616445

GenCC curated gene-disease

Mondo (2): autosomal recessive severe congenital neutropenia due to JAGN1 deficiency (MONDO:0014456), candidiasis, familial, 9 (MONDO:0014642)

Orphanet (2): Chronic mucocutaneous candidiasis (Orphanet:1334), Severe congenital neutropenia due to JAGN1 deficiency (Orphanet:423384)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST012489_52	Heel bone mineral density x serum urate levels interaction	5.000000e-08

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0004531	urate measurement
EFO:0009270	heel bone mineral density

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL5483004 (PROTEIN COMPLEX)

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: catalytic receptor — IL-17 receptor family

ChEMBL bioactivities

73 potent at pChembl≥5 of 75 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.85	IC50	1.4	nM	CHEMBL5414591
8.85	IC50	1.4	nM	CHEMBL5400846
8.77	IC50	1.7	nM	CHEMBL5422103
8.77	IC50	1.7	nM	CHEMBL5619911
8.54	IC50	2.9	nM	CHEMBL5438651
8.52	IC50	3	nM	CHEMBL5414048
8.48	IC50	3.3	nM	CHEMBL5419043
8.38	IC50	4.2	nM	CHEMBL5430856
8.36	IC50	4.4	nM	CHEMBL5400846
8.35	IC50	4.5	nM	CHEMBL5430936
8.31	IC50	4.9	nM	CHEMBL5401395
8.27	IC50	5.4	nM	CHEMBL5394125
8.26	IC50	5.5	nM	CHEMBL5417150
8.25	IC50	5.6	nM	CHEMBL5618410
8.21	IC50	6.2	nM	CHEMBL5423170
8.20	IC50	6.3	nM	CHEMBL5424668
8.19	IC50	6.4	nM	CHEMBL5410548
8.15	IC50	7	nM	CHEMBL5439897
8.10	IC50	7.9	nM	CHEMBL5414220
8.09	IC50	8.1	nM	CHEMBL5415927
8.05	IC50	9	nM	CHEMBL5415066
8.04	IC50	9.2	nM	CHEMBL5420382
8.02	IC50	9.6	nM	CHEMBL5427574
7.98	IC50	10.4	nM	CHEMBL5412206
7.95	IC50	11.3	nM	CHEMBL5422995
7.93	IC50	11.8	nM	CHEMBL5407942
7.92	IC50	12	nM	CHEMBL5437605
7.92	IC50	12	nM	CHEMBL5417062
7.82	IC50	15	nM	CHEMBL5620040
7.58	IC50	26.4	nM	CHEMBL5439089
7.33	IC50	47	nM	CHEMBL5618612
7.31	IC50	48.8	nM	CHEMBL5396605
7.17	IC50	68	nM	CHEMBL5619116
7.14	IC50	73	nM	CHEMBL5619950
7.08	IC50	83	nM	CHEMBL5619039
7.07	IC50	86	nM	CHEMBL5619162
7.05	IC50	89	nM	CHEMBL5618090
6.97	IC50	108	nM	CHEMBL5620164
6.94	IC50	116	nM	CHEMBL5618934
6.92	IC50	119	nM	CHEMBL5618722
6.78	IC50	166	nM	CHEMBL5428650
6.77	IC50	171	nM	CHEMBL5439961
6.75	IC50	180	nM	CHEMBL5411068
6.68	IC50	211	nM	CHEMBL5428530
6.59	IC50	254	nM	CHEMBL5403673
6.59	IC50	254	nM	CHEMBL5618262
6.54	IC50	288	nM	CHEMBL5421972
6.48	IC50	328	nM	CHEMBL5439819
6.40	IC50	400	nM	CHEMBL5396237
6.38	IC50	414	nM	CHEMBL5409554

PubChem BioAssay actives

73 with measured affinity, of 112 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
2-[(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-3-[(2-amino-2-oxoethyl)carbamoyl]-36-[(2S)-butan-2-yl]-24-(hydroxymethyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-27-methyl-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracont-12-yl]acetic acid	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0014	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N,12-bis(2-amino-2-oxoethyl)-36-[(2S)-butan-2-yl]-24-(hydroxymethyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-27-methyl-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2128205: Inhibition of interleukin-17RE/biotinylated IL-17C protein-protein interaction (unknown origin) incubated for 1 hrs by competitive ELISA	ic50	0.0014	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N,12-bis(2-amino-2-oxoethyl)-36-[(2S)-butan-2-yl]-27-(3-carbamimidamidopropyl)-24-(hydroxymethyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0017	uM
2-[(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-3-[(2-amino-2-oxoethyl)carbamoyl]-36-[(2S)-butan-2-yl]-27-(3-carbamimidamidopropyl)-24-(hydroxymethyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracont-12-yl]acetic acid	2128205: Inhibition of interleukin-17RE/biotinylated IL-17C protein-protein interaction (unknown origin) incubated for 1 hrs by competitive ELISA	ic50	0.0017	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N-(2-amino-2-oxoethyl)-36-[(2S)-butan-2-yl]-12-[(1S)-1-hydroxyethyl]-24-(hydroxymethyl)-18,27,30,33,42-pentakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0029	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N-(2-amino-2-oxoethyl)-27-benzyl-36-[(2S)-butan-2-yl]-12-(3-carbamimidamidopropyl)-24-(hydroxymethyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0030	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N-(2-amino-2-oxoethyl)-12,24-bis(hydroxymethyl)-18,27,30,33,42-pentakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-36-propan-2-yl-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0033	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-12-(4-aminobutyl)-N-(2-amino-2-oxoethyl)-36-[(2S)-butan-2-yl]-24-(hydroxymethyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-27-methyl-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0042	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N,12-bis(2-amino-2-oxoethyl)-24,36-bis[(2S)-butan-2-yl]-27-(3-carbamimidamidopropyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0045	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33R,36S,39S,42S)-N-(2-amino-2-oxoethyl)-36-[(2S)-butan-2-yl]-12,24-bis(hydroxymethyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-5-ylmethyl)-27-methyl-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0049	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N-(2-amino-2-oxoethyl)-27-(3-carbamimidamidopropyl)-12,24-bis(hydroxymethyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-5-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-36-propan-2-yl-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0054	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N,12-bis(2-amino-2-oxoethyl)-24-(hydroxymethyl)-18,27,30,33,42-pentakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21,36-tris(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0055	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N,12-bis(2-amino-2-oxoethyl)-36-(3-amino-3-oxopropyl)-24-[(2R)-butan-2-yl]-27-(3-carbamimidamidopropyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2128205: Inhibition of interleukin-17RE/biotinylated IL-17C protein-protein interaction (unknown origin) incubated for 1 hrs by competitive ELISA	ic50	0.0056	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N-(2-amino-2-oxoethyl)-27-benzyl-36-[(2S)-butan-2-yl]-24-(hydroxymethyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-12,39-bis(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0062	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N-(2-amino-2-oxoethyl)-24,36-bis[(2S)-butan-2-yl]-27-(3-carbamimidamidopropyl)-12-(hydroxymethyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0063	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N,12-bis(2-amino-2-oxoethyl)-24-(hydroxymethyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21,36-tris(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-27-propan-2-yl-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0064	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N-(2-amino-2-oxoethyl)-36-[(2S)-butan-2-yl]-12,24,27-tris(hydroxymethyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0070	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N-(2-amino-2-oxoethyl)-27-(3-amino-3-oxopropyl)-12,24-bis(hydroxymethyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-36-propan-2-yl-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0079	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N-(2-amino-2-oxoethyl)-36-(3-amino-3-oxopropyl)-12,24-bis(hydroxymethyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-27-propan-2-yl-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0081	uM
(6S,9S,12S,15S,18S,21S,24S,27S,30S,36R,42S,45S)-N-(2-amino-2-oxoethyl)-12-(hydroxymethyl)-6,15,18,21,30-pentakis[(4-hydroxyphenyl)methyl]-27-(1H-imidazol-4-ylmethyl)-9,42-bis(2-methylpropyl)-2,5,8,11,14,17,20,23,26,29,32,38,41,44-tetradecaoxo-24-propan-2-yl-34-thia-1,4,7,10,13,16,19,22,25,28,31,37,40,43-tetradecazabicyclo[43.3.0]octatetracontane-36-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0090	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N-(2-amino-2-oxoethyl)-36-[(2S)-butan-2-yl]-24-(hydroxymethyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-12,27-dimethyl-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0092	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N,12-bis(2-amino-2-oxoethyl)-24-(hydroxymethyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-27-methyl-9,21,36-tris(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0096	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N,12-bis(2-amino-2-oxoethyl)-36-(3-amino-3-oxopropyl)-24-(hydroxymethyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-27-propan-2-yl-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0104	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N,12-bis(2-amino-2-oxoethyl)-24-[(2S)-butan-2-yl]-27-(3-carbamimidamidopropyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21,36-tris(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0113	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N,12-bis(2-amino-2-oxoethyl)-18,27,30,33,42-pentakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-2-ylmethyl)-24-methyl-9,21,36-tris(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0118	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N-(2-amino-2-oxoethyl)-36-[(2S)-butan-2-yl]-24-(hydroxymethyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-27-methyl-9,12,21-tris(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0120	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N-(2-amino-2-oxoethyl)-12,24-bis(hydroxymethyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21,36-tris(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-27-propan-2-yl-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0120	uM
3-[(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-3-[(2-amino-2-oxoethyl)carbamoyl]-36-(3-amino-3-oxopropyl)-24-[(2S)-butan-2-yl]-27-(3-carbamimidamidopropyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracont-12-yl]propanoic acid	2128205: Inhibition of interleukin-17RE/biotinylated IL-17C protein-protein interaction (unknown origin) incubated for 1 hrs by competitive ELISA	ic50	0.0150	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N,12-bis(2-amino-2-oxoethyl)-36-(3-amino-3-oxopropyl)-27-(3-carbamimidamidopropyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21,24-tris(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0264	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N,12-bis(2-amino-2-oxoethyl)-24-[(2S)-butan-2-yl]-27-(3-carbamimidamidopropyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-36,39-bis(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2128205: Inhibition of interleukin-17RE/biotinylated IL-17C protein-protein interaction (unknown origin) incubated for 1 hrs by competitive ELISA	ic50	0.0470	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N,12-bis(2-amino-2-oxoethyl)-27-(3-carbamimidamidopropyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21,24,36-tetrakis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.0488	uM
3-[(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-3-[(2-amino-2-oxoethyl)carbamoyl]-24-[(2S)-butan-2-yl]-27-(3-carbamimidamidopropyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21,36-tris(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracont-12-yl]propanoic acid	2128205: Inhibition of interleukin-17RE/biotinylated IL-17C protein-protein interaction (unknown origin) incubated for 1 hrs by competitive ELISA	ic50	0.0680	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-12-(4-aminobutyl)-N-(2-amino-2-oxoethyl)-24-[(2S)-butan-2-yl]-27-(3-carbamimidamidopropyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-36,39-bis(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2128205: Inhibition of interleukin-17RE/biotinylated IL-17C protein-protein interaction (unknown origin) incubated for 1 hrs by competitive ELISA	ic50	0.0730	uM
2-[(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-3-[(2-amino-2-oxoethyl)carbamoyl]-24-[(2S)-butan-2-yl]-27-(3-carbamimidamidopropyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-36,39-bis(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracont-12-yl]acetic acid	2128205: Inhibition of interleukin-17RE/biotinylated IL-17C protein-protein interaction (unknown origin) incubated for 1 hrs by competitive ELISA	ic50	0.0830	uM
3-[(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-3-[(2-amino-2-oxoethyl)carbamoyl]-24-[(2S)-butan-2-yl]-27-(3-carbamimidamidopropyl)-36-(2-carboxyethyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracont-12-yl]propanoic acid	2128205: Inhibition of interleukin-17RE/biotinylated IL-17C protein-protein interaction (unknown origin) incubated for 1 hrs by competitive ELISA	ic50	0.0860	uM
3-[(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-36-(4-aminobutyl)-3-[(2-amino-2-oxoethyl)carbamoyl]-24-[(2S)-butan-2-yl]-27-(3-carbamimidamidopropyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracont-12-yl]propanoic acid	2128205: Inhibition of interleukin-17RE/biotinylated IL-17C protein-protein interaction (unknown origin) incubated for 1 hrs by competitive ELISA	ic50	0.0890	uM
3-[(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-3-[(2-amino-2-oxoethyl)carbamoyl]-24-[(2S)-butan-2-yl]-27,36-bis(3-carbamimidamidopropyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracont-12-yl]propanoic acid	2128205: Inhibition of interleukin-17RE/biotinylated IL-17C protein-protein interaction (unknown origin) incubated for 1 hrs by competitive ELISA	ic50	0.1080	uM
3-[(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-27-(4-aminobutyl)-3-[(2-amino-2-oxoethyl)carbamoyl]-24-[(2S)-butan-2-yl]-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-36,39-bis(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracont-12-yl]propanoic acid	2128205: Inhibition of interleukin-17RE/biotinylated IL-17C protein-protein interaction (unknown origin) incubated for 1 hrs by competitive ELISA	ic50	0.1160	uM
3-[(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-3-[(2-amino-2-oxoethyl)carbamoyl]-24-[(2S)-butan-2-yl]-27-(3-carbamimidamidopropyl)-18,30,33,36,42-pentakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracont-12-yl]propanoic acid	2128205: Inhibition of interleukin-17RE/biotinylated IL-17C protein-protein interaction (unknown origin) incubated for 1 hrs by competitive ELISA	ic50	0.1190	uM
3-[(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-3-[(2-amino-2-oxoethyl)carbamoyl]-24-[(2S)-butan-2-yl]-27-(3-carbamimidamidopropyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-36,39-bis(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracont-12-yl]propanoic acid	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.1660	uM
3-[(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-3-[(2-amino-2-oxoethyl)carbamoyl]-33-benzyl-24-[(2S)-butan-2-yl]-27-(3-carbamimidamidopropyl)-18,30,42-tris[(4-hydroxyphenyl)methyl]-36,39-bis(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracont-12-yl]propanoic acid	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.1710	uM
(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N-(2-amino-2-oxoethyl)-24-[(2S)-butan-2-yl]-27-(3-carbamimidamidopropyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-36,39-bis(1H-imidazol-4-ylmethyl)-12-methyl-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.1800	uM
(3R,9S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-N-(2-amino-2-oxoethyl)-24-[(2S)-butan-2-yl]-27-(3-carbamimidamidopropyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-36,39-bis(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.2110	uM
3-[(4S,7S,10S,13S,16S,19S,22S,25S,28S,34S,37S,43R)-43-[(2-amino-2-oxoethyl)carbamoyl]-19-(3-carbamimidamidopropyl)-4,13,16,28-tetrakis[(4-hydroxyphenyl)methyl]-7,10-bis(1H-imidazol-4-ylmethyl)-22-methyl-25,37-bis(2-methylpropyl)-2,5,8,11,14,17,20,23,26,29,32,35,38,41-tetradecaoxo-1-thia-3,6,9,12,15,18,21,24,27,30,33,36,39,42-tetradecazacyclotetratetracont-34-yl]propanoic acid	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.2540	uM
3-[(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-3-[(2-amino-2-oxoethyl)carbamoyl]-27-(3-carbamimidamidopropyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-36,39-bis(1H-imidazol-4-ylmethyl)-24-methyl-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracont-12-yl]propanoic acid	2128205: Inhibition of interleukin-17RE/biotinylated IL-17C protein-protein interaction (unknown origin) incubated for 1 hrs by competitive ELISA	ic50	0.2540	uM
3-[(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-3-[(2-amino-2-oxoethyl)carbamoyl]-27-(3-carbamimidamidopropyl)-24-[(1R)-1-hydroxyethyl]-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-36,39-bis(1H-imidazol-4-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracont-12-yl]propanoic acid	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.2880	uM
(3R,9S,12S,15S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-12-(4-aminobutyl)-N-(2-amino-2-oxoethyl)-15,24-bis(3-amino-3-oxopropyl)-21,36-bis[(2S)-butan-2-yl]-27-(3-carbamimidamidopropyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-39-(1H-imidazol-4-ylmethyl)-9-(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracontane-3-carboxamide	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.3280	uM
3-[(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-3-[(2-amino-2-oxoethyl)carbamoyl]-24-[(2S)-butan-2-yl]-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-36,39-bis(1H-imidazol-4-ylmethyl)-27-methyl-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracont-12-yl]propanoic acid	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.4000	uM
3-[(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-3-[(2-amino-2-oxoethyl)carbamoyl]-27-(3-carbamimidamidopropyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-36-(1H-imidazol-4-ylmethyl)-39-(1H-imidazol-5-ylmethyl)-9,21-bis(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-24-propan-2-yl-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracont-12-yl]propanoic acid	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.4140	uM
3-[(3R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42S)-3-[(2-amino-2-oxoethyl)carbamoyl]-9,24-bis[(2S)-butan-2-yl]-27-(3-carbamimidamidopropyl)-18,30,33,42-tetrakis[(4-hydroxyphenyl)methyl]-36,39-bis(1H-imidazol-4-ylmethyl)-21-(2-methylpropyl)-5,8,11,14,17,20,23,26,29,32,35,38,41,44-tetradecaoxo-1-thia-4,7,10,13,16,19,22,25,28,31,34,37,40,43-tetradecazacyclopentatetracont-12-yl]propanoic acid	2010347: Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	ic50	0.4220	uM

CTD chemical–gene interactions

19 total (human), top 19 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Acetaminophen	decreases expression	2
Benzo(a)pyrene	decreases expression, decreases methylation, increases methylation	2
Tobacco Smoke Pollution	decreases expression, increases methylation	2
aristolochic acid I	increases expression	1
ethyl-p-hydroxybenzoate	increases expression	1
sodium arsenite	affects expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
clothianidin	decreases expression	1
jinfukang	affects cotreatment, decreases expression	1
Cisplatin	affects cotreatment, decreases expression	1
Dexamethasone	increases expression	1
Drugs, Chinese Herbal	decreases expression	1
Estradiol	affects cotreatment, decreases expression	1
Niclosamide	increases expression	1
Smoke	decreases expression	1
Triclosan	increases expression	1
Urethane	decreases expression	1
Fluorescein-5-isothiocyanate	affects binding	1

ChEMBL screening assays

2 unique, capped per target: 2 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL5363915	Binding	Inhibition of IL-17C/IL-17RE interaction (unknown origin) incubated for 1.5 hrs by ELISA method	PepScaf: Harnessing Machine Learning with In Vitro Selection toward De Novo Macrocyclic Peptides against IL-17C/IL-17RE Interaction. — J Med Chem

Cellosaurus cell lines

1 cell lines: 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A8CK	HEK-Blue IL-17C	Transformed cell line	Female

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.